Clinical Application of Circulating Tumor Cells in Ovarian Cancer
HE Yu-nan
ZHANG Yu
Abstract：Liquid biopsy (LB), as a new generation detection technology, can more accurately evaluate the disease progress of tumor patients and become a valuable management tool of clinical medicine, which is expected to improve outcome of ovarian malignant tumor. It can be used in early screening, curative effect, assessing drug-resistance, relapse and prognosis of ovarian cancer via monitoring quantity changes of circulating tumor cells (CTCs) in body fluid. Comparing present clinical strategy depended on tumor markers, CTCs exhibit higher specificity and can be cytologically analyzed and cultured. However, the relationship between CTCs and the disease progression of ovarian tumors is not yet clear. Besides, more advanced molecular enrichment strategies needs to be applied to ovarian CTCs.
Keywords：Ovarian neoplasmsEarly diagnosisTumor markersbiologicalCirculating tumor cells
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 318-321 )